ABSTRACT
<p><b>OBJECTIVE</b>To revalidate the conversion factor（CF）for the conversion of BCR-ABL （P210）transcript levels to the international scale（BCR- ABLIS）in chronic myeloid leukemia（CML） which validated before.</p><p><b>METHODS</b>Peking University People's Hospital（PKUPH）prepared the exchange samples for revalidation of CFs of 15 laboratories which validated nine or eighteen months ago. The fresh BCR-ABL（P210）（+）bone morrow or peripheral blood nucleated cells were diluted with BCR-ABL （P210）（-）cells to achieve different BCR- ABL levels, totally 16 sets and 24 samples per set were prepared. TRIzol reagent was added in each tube. Each laboratory tested BCR-ABL transcript levels of one set of samples. Agreement between BCR-ABLIS of each laboratory and PKUPH was assessed by the Bland- Altman method. For laboratories which did not meet the criteria of revalidation, linear regression equation was derived after the samples with maximum BCR-ABL deviation were removed until R²>0.98, then new CF was calculated.</p><p><b>RESULTS</b>10 laboratories met the revalidation criteria with both bias within ±1.4 fold and 95% limits of agreement within ±6 folds, and their CFs still could be used for accurately conversion of BCR-ABLIS. New CFs were recalculated as of 1.8-6.3 folds of their previous CFs in 5 laboratories not met the criteria.</p><p><b>CONCLUSION</b>Revalidation of CF by sample exchange among laboratories was necessary for accurate and continuous application of BCR-ABLIS, which not only tested the validity of CF acquired before but also calculated new available CFs for those with invalid CFs.</p>
Subject(s)
Humans , Bone Marrow Cells , Fusion Proteins, bcr-abl , Genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Diagnosis , GeneticsABSTRACT
<p><b>OBJECTIVE</b>To validate the conversion factor (CF) for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia (CML).</p><p><b>METHODS</b>In 2012, the international reference laboratory in Adelaide, Australia (IMVS) sent two batches of RNA samples, 30 samples per batch, to Peking University People's Hospital (PKUPH). By comparing BCRABL (P210) transcript levels reported by the two laboratories, CF of PKUPH was calculated and validated by IMVS. In 2013, PKUPH prepared the exchange samples for validation of CF of 9 hospitals who have calculated CFs before. The fresh BCR-ABL (P210) (+) cells were serially diluted by BCR-ABL (P210) (-) cells to prepare 22 kinds of samples with different BCR-ABL transcript levels, each kind had 10 parallel samples. Trizol reagent was added in each tube. Ten hospitals tested BCR-ABL transcript levels of one set of 22 samples. Agreement between BCR-ABL transcript levels of each laboratory and PKUPH was assessed by the Bland-Altman method.</p><p><b>RESULTS</b>PKUPH successfully validated its CF with bias 1.1 fold and 95% limits of agreement between -4.7 and 4.9 fold. Of 9 hospitals whose validation performed by sample exchanges with PKUPH, 6 hospitals successfully validated their CF with bias ≤±1.4 fold and 95% limits of agreement within ±6 fold.</p><p><b>CONCLUSION</b>Validation of CF examined the stability of the detection of BCR-ABL (P210) transcript levels, which was necessary for the valid conversion of BCR-ABL (P210) transcript levels to the international scale in CML.</p>
Subject(s)
Humans , Fusion Proteins, bcr-abl , Genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Genetics , Reverse Transcriptase Polymerase Chain Reaction , Reference Standards , Transcription, GeneticABSTRACT
Aim To study the inhibitory effects of F951,a novel bcl-2 antisense oligodeoxynucleotide,on expression of bcl-2,growth of tumor and survival time of nude mice transplanted subcutaneously with acute myeloid leukemia.Methods HL-60 cells with high expression of bcl-2 were proliferated in vitro.The models of the nude mice with HL-60 cells were established by subcutaneous transplantation with drugs directly injected.The effects of F951 and F951 with low dose Ara-c on growth of tumor and survival time of mice with tumor were observed.The expressions of bcl-2 mRNA in the tumors implanted were detected by fluorescent quantitation RT-PCR.The morphologic structure of tumor tissues was assayed by light microscope.Results After each group mice with tumors were treated for 14 days,the volume,the weight of tumor and the bcl-2 mRNA expression of tumor tissue were shown respectively as follows: NS control group(15.17?3.40)cm3、(12.69?0.92)g、9.79?104 Copies??g-1;FNS group(15.91?3.77)cm3,(12.38?1.21)g;8.31?104 Copies??g-1;Ara-C group(1.24?0.55)cm3,(2.32?0.49)g,2.59?104 Copies??g-1;F951 group(2.6?1.55)cm3,(3.53?0.67)g;1.01?103 Copies??g-1;F951+Ara-C group(0.62?0.48)cm3,(1.05?0.63)g,9.5?102 Copies??g-1.The data above showed that F951 could downregulate the expression of bcl-2 in nude mice with HL-60 cells xenograft and inhibit growth of tumor.The growth of tumor of F951 group was reduced,and the inhibitory rate was 72.18%,there was significant difference comparing control groups with NS and FNS(P
ABSTRACT
Aim To observe the apoptosis of human leukemic cells induced by F951, a novel bcl-2 antisense oligodeoxynucleotide. Methods HL60 cells were cultured with F951 in variant doses. Apoptotic cells were detected by flow cytometry, DNA ladder, electron microscope observation and terminal-deoxynucleotidyl transferase mediated nick end labeling (TUNEL). Results After HL60 cells were treated for 48 hours, mitochondria apoptotic cells can be detected at the ratio of 3.00% in the untreated group, 13.57% in the FNS control group and 30.95%, 38.08%, 52.55% with 5, 10, 20 ?mol?L-1 F951 respectively; the ratio of cells with caspase activity was 0.08% in the untreated group, 0.14% in the FNS control group and 43.68%, 60.54%, 80.37% with 5, 10, 20 ?mol?L-1 F951 respectively. Typical DNA ladder was seen from gel electrophoresis in F951 treated groups, and more apparent effect in the aspect of inducing DNA ladder had been observed with the improvement of F951 concentration. Detected through TUNEL and electron microscope, apoptotic cells in untreated group and FNS control group can only be found by chance, but very commonly seen in F951 treated groups and more frequently with the improvement of F951 concentration. Conclusion F951 can induce cell apoptosis in HL60 cells. Such effect is achieved through the inhibition of bcl-2 gene expression by F951 which initialize apoptosis passageway in consequence.
ABSTRACT
Aim To investigate whether F951,a novel Bcl-2 antisense oligodeoxynucleotide,down-regulates Bcl-2 expression in HL60 cells and inhibits HL-60 cells proliferation.Methods HL60 cells were cultured with F951 in variant doses.The proliferation of HL60 cells was assayed by MTT and Typan Blue exclusion test.Expression of Bcl-2 protein and its mRNA was measured by FACS and RT-PCR respectively.The apoptotic cells were detected by DNA ladder.Results After HL60 cells were treated with F951 in 5,10,20 ?mol?L~(-1) doses respectively for 1～5 days,they showed apparent inhibition of proliferation.With the improvement of the concentration of F951 and the prolongation of the time of treatment, F951 showed stronge effect in the aspect of inhibiting the HL60 cells proliferation.It was determined with MTT method that the inhibition rates of HL60 cells treated with 5,10,20 ?mol?L~(-1) F951 were 20.56%, 37.66%, 54.11% respectively. F951 significantly down-regulated the expression of Bcl-2 mRNA and protein in the HL60 cells.Typical DNA ladder was seen from gel electrophoresis. With the improvement of the concentration of F951,it showed more apparent effect in the aspect of inducing DNA ladder.Conclusion F951 can inhibit cells proliferation through down-regulating Bcl-2 gene expression and promoting cells apoptosis in HL60 cells.